Clinical Trial

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Study acronym: UHKT-CAR19-01
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2025 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-09-13; most recent amendment 2025-01-03.
Trial Details
NCT Number NCT05054257
Lead Sponsor Institute of Hematology and Blood Transfusion, Czech Republic
Conditions Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed
Enrollment 10 participants
Start Date 2021-06-02
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-12-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-06